Graphique du cours de l'action ALNY
ALNY Gagner
Alnylam Pharmaceuticals Inc
$297.92
0.61%
$1.81
À la fermeture : May 04, 16:00:00 GMT-4
$299.42
0.5%
$1.5
Post-Marché: May 04, 20:00:00 GMT-4
Retour
Alnylam Pharmaceuticals Inc (ALNY) Gagner
Statistiques clés
Clôture préc.
$296.11
Prix d'ouverture
$298
Plage de la journée
$288.05 - $300.49
Plage de 52 semaines
$214.76 - $495.55
Volume
1.5M
Volume moyen
1.4M
Rendement en dividend
--
BPA (TTM)
2.25
Capitalisation boursière
$39.7B
Qu’est-ce que ALNY ?
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 2,500 full-time employees. The company went IPO on 2004-05-28. The firm is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. The company is developing Cemdisiran to treat complement-mediated diseases.
Fonctionnalités
© 2026 Edgen fonctionné par